CAPIVASERTIB - Generic Drug Details

What are the generic drug sources for capivasertib and what is the scope of freedom to operate?

Capivasertib is the generic ingredient in one branded drug marketed by Astrazeneca and is included in one NDA. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Capivasertib has eighty-seven patent family members in forty-two countries.

One supplier is listed for this compound.

Summary for CAPIVASERTIB

International Patents:	87
US Patents:	8
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	23
What excipients (inactive ingredients) are in CAPIVASERTIB?	CAPIVASERTIB excipients list
DailyMed Link:	CAPIVASERTIB at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for CAPIVASERTIB

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for CAPIVASERTIB

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Taiwan University Hospital	Phase 2
VA Office of Research and Development	Phase 2
Quotient Sciences	Phase 1

See all CAPIVASERTIB clinical trials

US Patents and Regulatory Information for CAPIVASERTIB

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	TRUQAP	capivasertib	TABLET;ORAL	218197-002	Nov 16, 2023		RX	Yes	Yes			Y	Y
Astrazeneca	TRUQAP	capivasertib	TABLET;ORAL	218197-002	Nov 16, 2023		RX	Yes	Yes			Y	Y
Astrazeneca	TRUQAP	capivasertib	TABLET;ORAL	218197-001	Nov 16, 2023		RX	Yes	No
Astrazeneca	TRUQAP	capivasertib	TABLET;ORAL	218197-001	Nov 16, 2023		RX	Yes	No			Y	Y
Astrazeneca	TRUQAP	capivasertib	TABLET;ORAL	218197-001	Nov 16, 2023		RX	Yes	No
Astrazeneca	TRUQAP	capivasertib	TABLET;ORAL	218197-002	Nov 16, 2023		RX	Yes	Yes
Astrazeneca	TRUQAP	capivasertib	TABLET;ORAL	218197-001	Nov 16, 2023		RX	Yes	No

International Patents for CAPIVASERTIB

Country	Patent Number	Title	Estimated Expiration
Israel	204721	(s)-4-אמינו-n-(1-(4-כלורופניל)-3-הידרוקסיפרופיל)-1-(h7-פירולו[3,2-d]פירימידינ-4-יל)פיפרידינ-4-קרבוקסאמיד ומלחים תואמים פרמצבטית, תכשירים רפואיים המכילים אותה, שימושה בהכנת תרופה לטיפול בסרטן, תהליכים להכנתה, וחומרי ביניים מועילים בתהליכים אלו ((s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, use thereof in the preparation of medicaments for the treatment of cancer, processes for its preparation and intermediates useful in said processes)
Malaysia	175052	CRYSTALLINE FORMS OF (S) -4-AMINO-N- (1- (4 - CHLOROPHENYL) - 3 - HYDROXYPROPYL) -1- (7H - PYRROLO [2, 3-D] PYRIMIDI N-4-YL) PIPERIDINE-4-CARBOXAMIDE
Mexico	2010003927	DERIVADOS DE PIRROLO [2,3-D] PIRIMIDINA COMO INHIBIDORES DE PROTEINAS CINASAS B. (PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS.)
Argentina	051342	DERIVADOS DE PURINA, PURINONA, DEAZAPURINA Y DEAZAPURINONA COMO INHIBIDORES DE LA ACTIVIDAD DE LA PROTEIN QUINASA; METODOS PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y SU USO EN LA ELABORACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA PROTEIN QUINA
Japan	2018039807	結晶形態の（Ｓ）−４−アミノ−Ｎ−（１−（４−クロロフェニル）−３−ヒドロキシプロピル）−１−（７Ｈ−ピロロ［２，３−ｄ］−ピリミジン−４−イル）ピペリジン−４−カルボキサミド ((S)-4-AMINO-N-(1-(4-CHLOROPHENYL)-3-HYDROXYPROPYL)-1-(7H-PYRROLO[2,3-D]-PYRIMIDINE-4-YL)PIPERIDINE-4-CARBOXAMIDE IN CRYSTAL FORM)
Dominican Republic	P2010000103	DERIVADOS DE PIRROLO [2,3-D] PIRIMIDINA COMO INHIBIDORES DE PROTEINAS QUINASAS B
Saudi Arabia	05260337	مركبات بيورين ودي آزابيورين لها فعالية مثبطة لإنزيم كيناز (purine and deazapurine compounds having kinase inhibiting activity)